Mode of administration-dependent pharmacokinetics of bisphosphonates and bioavailability determination

International Journal of Pharmaceutics

Volumn 220, Issue 1-2, 2001, Pages 1-11

  Hoffman, Amnon ^a   Stepensky, David ^a   Ezra, Aviva ^a   Van Gelder, Joel M ^a   Golomb, Gershon ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Bioavailability; Bisphosphonate; Mode of administration dependency; Nonlinear pharmacokinetics; Pharmacokinetics; Volume of distribution

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; SUBEROYLBISPHOSPHONATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG TISSUE LEVEL; KIDNEY; LIVER; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DIPHOSPHONATES; HALF-LIFE; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; INTESTINAL ABSORPTION; KIDNEY; LIVER; MALE; METABOLIC CLEARANCE RATE; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0035806258     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(01)00654-8     Document Type: Article

References (21)

1. Body J., Coleman R., Piccart M. Use of bisphosphonates in cancer patients. Cancer Treat. Rev. 22:1996;265-287.
2. Bonjour J.-P., Rizzoli R., Ammann P., Chevalley T. Bisphosphonates in clinical medicine. Heersche J.N.M., Kanis J.A. Bone and Mineral Research. 8:1994;205-264 Elsevier, Amsterdam.
3. Bounameaux H., Schifferli J., Montani J., Jung A., Chatelanat F. Renal failure associated with intravenous bisphosphonates. Lancet. 1:1983;471.
4. Fleisch H. New bisphosphonates in osteoporosis. Osteoporos. Mon. Suppl. 2:1993;S15-S22.
5. Fleisch H. Bisphosphonates in Bone Disease. From the Laboratory to the Patient. 1997;The Parthenon Publishing Group, Berne.
6. Gibaldi M., Perrier D. Pharmacokinetics. 1982;Marcel Dekker, New York.
7. Golomb G., Wagner D. Development of a new in vitro model for studying implantable polyurethane calcification. Biomaterials. 12:1991;397-405.
8. 3H] tetracycline kinetics and indices of kidney function facilitate study of the activity and toxic effects of bisphosphonates in bone resorption. Pharm. Res. 9:1992;1018-1023.
9. Golomb G., Schlossman A., Saadeh H., Levi M., Van Gelder J.M., Breuer E. Bisacylphosphonates inhibit hydroxyapatite formation and dissolution in vitro and dystrophic calcification in vivo. Pharm. Res. 9:1992;143-148.
10. Hoffman A., Levy G. Kinetics of drug action in disease states XXIX. Effect of experimental nephrotic syndrome on the pharmacodynamics of heptabarbital: implications of severe hypoalbuminemia. J. Pharmacol. Exp. Ther. 249:1989;117-122.
11. Hyldstrup L., Fleisch G., Hauffe S. Pharmacokinetic evaluation of pamidronate after oral administration: a study on dose proportionality, absolute bioavailability, and effect of repeated administration. Calcif. Tissue Mon. 53:1993;297-300.
12. Kautiamen S., Luurila S., Ylitalo P., Ylitalo R. Transformation of bisphosphonates into insoluble material in human blood in vitro. Methods Find. Exp. Clin. Pharmacol. 20:1998;289-295.
13. Lin J. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 18:1996;75-85.
14. Lin J.H., Chen I.-W., Deluna F.A. Nonlinear kinetics of alendronate. Plasma protein binding and bone uptake. Drug Metab. Dispos. 22:1994;400-405.
15. Lin J.H., Lu A. Role of pharmacokinetics and metabolism in drug discovery and development. Pharm. Rev. 49:1997;403-431.
16. Michael W., King W., Wakim J. Metabolism of disodium ethane-1-hydroxy1,1,diphosphonate (disodium etidronate) in the rat, rabbit, dog and monkey. Toxicol. Appl. Pharmacol. 21:1972;503-515.
17. Monkkonen J., Ylitalo P. The tissue distribution of clodronate (dichloromethylene bisphosphonate) in mice. The effects of vehicle and the route of administration. Eur. J. Drug Metab. Pharmacokinet. 15:1990;239-243.
18. Osterman T., Junakoski A., Lauren L., Sellman R. Effect of iron on the absorption and distribution of clodronate after oral administration in rats. Pharmacol. Toxicol. 74:1994;267-270.
19. Rosen C., Kessenich C. Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone disease. Drugs. 51:1996;537-551.
20. Van Gelder J.M., Breuer E., Omoy A., Schlossman A., Patlas N., Golomb G. Anticalcification and antiresorption effects of bisacylphosphonates. Bone. 16:1995;511-520.
21. Wingen F., Schmahl D. Pharmacokinetics of the osteotropic diphosphonate 3-amino-1-hydroxypropane-1,1-diphosphonic acid in mammals. Arzneim.-Forsch. 37:1987;1037-1042.